We at Tzar Labs are excited to introduce a groundbreaking advancement in neurological diagnostics: our innovative blood-based biopsy technology. This non-invasive approach offers unprecedented insights into brain health, providing a significant alternative to traditional, more invasive diagnostic procedures.

Our technology leverages the power of Next Generation Sequencing (NGS) to analyse a unique population of circulating pluripotent stem cells. These cells, which appear in the bloodstream early when an organ is under stress, are an indication of potential neurological changes.

Specifically, we perform Whole Transcriptome Sequencing on these stem cells, yielding data comparable to traditional tissue biopsies. This enables the early detection of molecular signatures associated with neurological disorders, including Alzheimer’s disease, dementia, and ALS.

Key Benefits for Neurologists:

• Non-Invasive Early Detection: Facilitates the identification of at-risk patients before the onset of clinical symptoms.
• Enhanced Diagnostic Accuracy: Provides detailed molecular information comparable to tissue biopsies.
• Personalised Treatment Strategies: Supports the development of targeted interventions based on individual patient profiles.
• Improved Patient Management: Enables proactive monitoring and early intervention, potentially altering disease trajectories.

This technology can potentially transform the landscape of neurological care, empowering clinicians with valuable tools for early diagnosis, prevention, and personalised treatment.

We are confident that our blood-based biopsy will be an invaluable asset for neurologists. We would be pleased to schedule a consultation to discuss the technology in greater detail and explore how it can benefit your patients.